Agile Therapeutics, Inc. (NASDAQ:AGRX)‘s stock had its “buy” rating reiterated by investment analysts at Noble Financial in a report issued on Sunday, July 30th.
Several other equities analysts also recently weighed in on the company. Janney Montgomery Scott reissued a “buy” rating and set a $15.00 target price on shares of Agile Therapeutics in a research report on Friday, July 21st. HC Wainwright started coverage on Agile Therapeutics in a research report on Wednesday, July 19th. They set a “buy” rating and a $10.00 price target on the stock. Royal Bank Of Canada set a $8.00 price objective on Agile Therapeutics and gave the stock a “buy” rating in a research note on Sunday, July 16th. ValuEngine upgraded Agile Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 8th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $9.00 price objective on shares of Agile Therapeutics in a report on Monday, May 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $9.08.
Shares of Agile Therapeutics (AGRX) opened at 3.48 on Friday. Agile Therapeutics has a 12-month low of $1.82 and a 12-month high of $8.15. The stock’s market capitalization is $100.24 million. The firm’s 50-day moving average is $4.02 and its 200 day moving average is $3.29.
Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.02. During the same period in the previous year, the firm earned ($0.29) earnings per share. On average, equities research analysts forecast that Agile Therapeutics will post ($1.05) EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in AGRX. Renaissance Technologies LLC increased its position in Agile Therapeutics by 209.2% in the fourth quarter. Renaissance Technologies LLC now owns 64,000 shares of the specialty pharmaceutical company’s stock valued at $365,000 after buying an additional 43,300 shares during the period. Royce & Associates LP increased its position in Agile Therapeutics by 206.1% in the first quarter. Royce & Associates LP now owns 987,582 shares of the specialty pharmaceutical company’s stock valued at $3,165,000 after buying an additional 665,000 shares during the period. Susquehanna International Group LLP purchased a new position in Agile Therapeutics during the second quarter valued at $205,000. Royal Bank of Canada increased its position in Agile Therapeutics by 608.0% in the second quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after buying an additional 27,907 shares during the period. Finally, Goldman Sachs Group Inc. purchased a new position in Agile Therapeutics during the second quarter valued at $309,000. Institutional investors and hedge funds own 67.40% of the company’s stock.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
What are top analysts saying about Agile Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agile Therapeutics Inc. and related companies.